Kwon-Sik Park

Education

  • PhD, University of Cincinnati
  • Postdoc, Stanford University

Primary Appointment

  • Associate Professor, Microbiology, Immunology, and Cancer Biology

Contact

Research Interest(s)

Mechanisms of organ development and homeostasis and tumor development

Research Description

Functional validation of genomic alterations in lung cancer. To determine oncogenic drivers of SCLC, we characterize genomic alterations in tumor progression using genetically engineered precancerous cells and mouse models. Our efforts are focused on three areas of interests as follows:

1. To better understand transcriptional program altered by frequent mutations in transcription factors and chromatin modifiers, we integrate functional genetics with omics approach.

2. To delineate signaling pathways for tumor progression and homeostasis, we study roles of developmental and growth factor signaling pathways that are deregulated during tumor development.

3. To determine role of metabolic plasticity in mutant cells during tumor progression, we aim to identify and characterize altered metabolic pathways in tumorigenesis and their relationships to oncogenic drivers.

Selected Publications

  • Kim D, Kim K, Kim K, Dunn C, Park K. Transcriptional deregulation underlying the pathogenesis of small cell lung cancer. Translational lung cancer research. 2018;7(1): 4-20. PMID: 29535909 | PMCID: PMC5835594
  • Ponath P, Menezes D, Pan C, Chen B, Oyasu M, Strachan D, LeBlanc H, Sun H, Wang X, Rangan V, Deshpande S, Cristea S, Park K, Sage J, Cardarelli P. A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018. PMID: 30021910
  • Denny S, Yang D, Chuang C, Brady J, Lim J, Grüner B, Chiou S, Schep A, Baral J, Hamard C, Antoine M, Wislez M, Kong C, Connolly A, Park K, Sage J, Greenleaf W, Winslow M. Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility. Cell. 2016. PMID: 27374332
  • Kim D, Wu N, Kim Y, Cheng P, Basom R, Kim D, Dunn C, Lee A, Kim K, Lee C, Singh A, Gazdar A, Harris C, Eisenman R, Park K, MacPherson D. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer. Genes & development. 2016;30(11): 1289-99. PMID: 27298335
  • George J, Lim J, Jang S, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan N, Park K, Yang D, Karnezis A, Vaka D, Torres A, Wang M, Korbel J, Menon R, Chun S, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel P, Petersen I, Chen Y, Soltermann A, Tischler V, Choi C, Kim Y, Massion P, Zou Y, Jovanovic D, Kontic M, Wright G, Russell P, Solomon B, Koch I, Lindner M, Muscarella L, la Torre A, Field J, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun O, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen H, Achter V, Lang U, Bogus M, Schneider P, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis W, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas S, Brambilla E, Peifer M, Sage J, Thomas R. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563): 47-53. PMID: 26168399
  • Jahchan N, Dudley J, Mazur P, Flores N, Yang D, Palmerton A, Zmoos A, Vaka D, Tran K, Zhou M, Krasinska K, Riess J, Neal J, Khatri P, Park K, Butte A, Sage J. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer discovery. 2013;3(12): 1364-77. PMID: 24078773 | PMCID: PMC3864571
  • Peifer M, Fernández-Cuesta L, Sos M, George J, Seidel D, Kasper L, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus H, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann J, Lu X, Carter S, Cibulskis K, Banerji S, Getz G, Park K, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella L, Fazio V, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Snijders P, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun O, Lund-Iversen M, Sänger J, Clement J, Soltermann A, Moch H, Weder W, Solomon B, Soria J, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider P, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp L, Brindle P, Haas S, Thomas R. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature genetics. 2012;44(10): 1104-10. PMID: 22941188
  • Park K, Liang M, Raiser D, Zamponi R, Roach R, Curtis S, Walton Z, Schaffer B, Roake C, Zmoos A, Kriegel C, Wong K, Sage J, Kim C. Characterization of the cell of origin for small cell lung cancer. Cell cycle (Georgetown, Tex.). 2011;10(16): 2806-15. PMID: 21822053 | PMCID: PMC3219544
  • Park K, Martelotto L, Peifer M, Sos M, Karnezis A, Mahjoub M, Bernard K, Conklin J, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown T, Markovic A, Devereux W, Ocasio C, Chen J, Stearns T, Thomas R, Dorsch M, Buonamici S, Watkins D, Peacock C, Sage J. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature medicine. 2011;17(11): 1504-8. PMID: 21983857 | PMCID: PMC3380617
  • Schaffer B, Park K, Yiu G, Conklin J, Lin C, Burkhart D, Karnezis A, Sweet-Cordero E, Sage J. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer research. 2010;70(10): 3877-83. PMID: 20406986 | PMCID: PMC2873158
  • Jia* D, Augert* A, Kim* DW, Eastwood E, Wu N, Ibrahim A, Pillai SPS, Kim KB, Dunn C, Gazdar A, Park# KS, MacPherson# D. Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition. Cancer Discovery. .
  • Yang D, Denny S, Greenside P, Chaikovsky A, Brady J, Ouadah Y, Granja J, Jahchan N, Lim JS, Kwok S, Kong CS, Berghoff A, Shmitt A, Reinhardt C, Park KS, Preusser M, Kundaje A, Greenleaf W, Sage J, Wonslow M. Inter-tumoral heterogeneity in SCLC is influenced by the cell-type of origin Cancer Discovery. .